Skip to content
buyModerate

Baker Bros. Advisors LP bought $37M of MDGL

director at MADRIGAL PHARMACEUTICALS, INC.. 97,065 shares at an average of $380.58, traded Aug 18, 2025, filed Aug 20, 2025.

Conviction score
46
Value
$37M
97,065 shares
Holdings after
1,947,968
+50% from before
From 52-week low
+93%
low $202.48, close $391.43
From 52-week high
0%
high $391.43, as of Aug 18, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $36.9M at market
    +25
  • Relative to holdings
    Holdings up 50%
    +6
  • Price context
    Mid range
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Aug 20, 2025: +20.4%SPY +23.7% · excess -3.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-25-110502, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 18, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,460$372.87$917k197,085Aug 20, 2025
Aug 18, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+26,704$372.87$10.0M1,885,795Aug 20, 2025
Aug 18, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+675$374.43$253k197,760Aug 20, 2025
Aug 18, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+7,325$374.43$2.7M1,893,120Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+480$380.44$183k198,240Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+5,209$380.44$2.0M1,898,329Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+176$380.78$67k198,416Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,919$380.78$731k1,900,248Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+873$381.12$333k199,289Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+9,477$381.12$3.6M1,909,725Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+105$382.29$40k199,394Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,136$382.29$434k1,910,861Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+262$382.82$100k199,656Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,838$382.82$1.1M1,913,699Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+373$383.79$143k200,029Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+4,049$383.79$1.6M1,917,748Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+1,248$385.06$481k201,277Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+13,545$385.06$5.2M1,931,293Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+409$387.07$158k201,686Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+4,441$387.07$1.7M1,935,734Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+34$389.00$13k201,720Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+366$389.00$142k1,936,100Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+231$389.89$90k201,951Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+2,506$389.89$977k1,938,606Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+862$392.24$338k202,813Aug 20, 2025
Aug 20, 2025POpen-market purchase
Common Stockindirect: See Footnotes
+9,362$392.24$3.7M1,947,968Aug 20, 2025

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
38Weak
MDGLsell 210b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$854k
1,982 shares
-14%
35Weak
MDGLsell 2
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$181k
419 shares
-3%
53Moderate
MDGLsell 2
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$505k
1,183 shares
-11%
12Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$449k
910 shares
-9%
10Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$13M
24,520 shares
-12%
0Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$154k
280 shares
-0%
25Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$14M
24,800 shares
-12%
20Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Rebecca Taub
director
$10M
18,650 shares
-4%
50Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$1.4M
2,400 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Baker Bros. Advisors LP bought $37M of MDGL | InsiderTell